The New Zealand Superannuation Fund posted a 3 percent return last month, benefiting from a rally in global equity markets. Returns for February totalled $550 million before tax of $30m.
The New Zealand Superannuation Fund posted a 3 percent return last month, benefiting from a rally in global equity markets.
Returns for February totalled $550 million before tax of $30m.
The fund, in which the Government has suspended automatic contributions to avoid further increasing debt, has returned 22.5 percent for the financial year since July.
That compares with a return of 15.5 percent last financial year. Returns were after fees, but before tax.
Created in 2003 to part-fund New Zealand's future superannuation costs, the fund has grown to just under $19 billion.
Global equities dominated the fund's holdings, at 62.6 percent, followed by international fixed income (11.2 percent) and infrastructure investments (8 percent).
The fund's largest investment in New Zealand equities was a $291m stake in Auckland International Airport, representing 1.5 percent of fund value.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- MARKET CLOSE: NZ shares gain as market bounce continues; Kathmandu, Fletcher rise
- New lawyers not doing 'much better' than job at McDonald's – report surprises
- Auditors warn of Seadragon's going concern ability as firm breaches covenant
- New hotel to go ahead in Auckland as govt looks to boost tourism investment
- Marlborough-based wine company lists on the NXT despite OIO hiccup
Most listened to
- Marlborough Wine Estates CEO Catherine Ma explains why the Chinese-owned company listed on the NXT
- National list MP Chris Bishop says Phil Twyford's accusation the government has made housing a 'race issue' is hypocritical
- Bond prices have fallen while oil prices have risen - Jason Walls explains why on Walls' Street
- NBR technology editor Chris Keall on hitting 4000 member subscribers
- In his Editor's Insight Nevil Gibson on the future of health information technology and medical devices industry